Host: |
HEK293 |
Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
Short Description: |
Recombinant-Human CD30/TNFRSF8-C-His-Avi protein was developed from hek293 and has a target region of C-His-Avi. For use in research applications. |
Conjugation: |
Biotin |
Formulation: |
Lyophilised from 0.2 µm filtered PBS solution pH7.4. |
Dilution Range: |
Upon receipt centrifuge vial to ensure maximal product extraction, recommended: 20sec, 5K RPM |
Storage Instruction: |
The lyophilized protein is stable for at least 1 year from date of receipt at-20°C. |
Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). |
Gene Symbol: |
TNFRSF8 |
Gene ID: |
943 |
Uniprot ID: |
TNR8_HUMAN |
Immunogen Region: |
Phe19-Lys379 |
Immunogen: |
DNA sequence encoding Human CD30/TNFRSF8 including a C-His-Avi tag was expressed in HEK293 Cells. The recombinant protein was then biotinylated site specific using the AVItag biotinylation technology. |
Post Translational Modifications | Phosphorylated on serine and tyrosine residues (Probable). Isoform 2 is constitutively phosphorylated. |
Function | Receptor for TNFSF8/CD30L. May play a role in the regulation of cellular growth and transformation of activated lymphoblasts. Regulates gene expression through activation of NF-kappa-B. |
Protein Name | Tumor Necrosis Factor Receptor Superfamily Member 8Cd30l ReceptorKi-1 AntigenLymphocyte Activation Antigen Cd30Cd Antigen Cd30 |
Database Links | Reactome: R-HSA-5669034 |
Cellular Localisation | Isoform 1: Cell MembraneSingle-Pass Type I Membrane ProteinIsoform 2: Cytoplasm |
Alternative Protein Names | Tumor Necrosis Factor Receptor Superfamily Member 8 proteinCd30l Receptor proteinKi-1 Antigen proteinLymphocyte Activation Antigen Cd30 proteinCd Antigen Cd30 proteinTNFRSF8 proteinCD30 proteinD1S166E protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance